XOMA Royalty (XOMA) Non-Current Debt (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Non-Current Debt came in at $88.8 million in Q1 2026, down 11.12% year-on-year from $99.9 million in Q1 2025, and down 7.91% quarter-over-quarter from $96.5 million in Q4 2025.
XOMA Royalty (XOMA) Non-Current Debt (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Non-Current Debt across 16 years of filings, most recently posting $88.8 million for Q1 2026.
- Non-Current Debt for Q1 2026 came in at $88.8 million, down 11.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.8 million (down 11.12% YoY), and the FY2025 annual result was $96.5 million, down 9.75% from the prior year.
- Non-Current Debt came in at $88.8 million for Q1 2026 at XOMA Royalty, down from $96.5 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $118.5 million in Q4 2023 to a low of $88.8 million in Q1 2026.
- The 4-year median for Non-Current Debt is $104.5 million (2024), against an average of $104.5 million.
- Peak annual rise in Non-Current Debt reached 9.75% in 2025, while the deepest fall reached 12.74% in 2025.
- XOMA Royalty's Non-Current Debt stood at $118.5 million in 2023, then fell by 9.82% to $106.9 million in 2024, then slipped by 9.75% to $96.5 million in 2025, then fell by 7.91% to $88.8 million in 2026.
- The last three Non-Current Debt figures came in at $88.8 million (Q1 2026), $96.5 million (Q4 2025), and $94.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 88.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.83 Mn |
| Mar 31, 2026 | 88.83 Mn |
| Dec 31, 2025 | 96.45 Mn |
| Dec 31, 2025 | 96.45 Mn |
| Sep 30, 2025 | 94.38 Mn |
| Sep 30, 2025 | 94.38 Mn |
| Jun 30, 2025 | 102.20 Mn |
| Jun 30, 2025 | 102.20 Mn |
| Mar 31, 2025 | 99.93 Mn |
| Mar 31, 2025 | 99.93 Mn |
| Dec 31, 2024 | 106.88 Mn |
| Dec 31, 2024 | 106.88 Mn |
| Sep 30, 2024 | 108.09 Mn |
| Sep 30, 2024 | 108.09 Mn |
| Jun 30, 2024 | 115.08 Mn |
| Jun 30, 2024 | 115.08 Mn |
| Mar 31, 2024 | 114.53 Mn |
| Mar 31, 2024 | 114.53 Mn |
| Dec 31, 2023 | 118.52 Mn |
| Dec 31, 2023 | 118.52 Mn |